Abstract: The present invention relates to the use of the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof in the treatment of SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer. More specifically, the present invention provides to the use of pharmaceutical compositions comprising the compound of formula (I) or the pharmaceutically acceptable salts and/or solvates thereof and at least one physiologically acceptable excipient in the treatment of a patient affected by SSTR3 expressing tumors, selected from non-functioning pituitary adenomas (NFPAs) or other neuroendocrine-related malignancies, selected from pancreatic tumors, pheochromocytomas, paragangliomas, lung carcinoids or breast cancer.

Abstract: The present invention relates a method based on mRNA biomarkers that can be used to define the efficacious dose and/or the biological activity of inhibitors of histone deacetylase 6 (HDAC6), such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl) benzamide, during the clinical treatment of patients affected by cancer. More in particular, the invention refers to the analysis of the gene expression's variation of specific biomarkers in human monocytes, as “gene expression signatures”, in a method to evaluate the clinical efficacy of HDAC6 inhibitors, such as the compound N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide.

Abstract: The present invention relates to a combination comprising N-hydroxy-4-((5-(thiophen-2-yl)-1H-tetrazol-1-yl)methyl)benzamide or a pharmaceutically acceptable salt thereof and at least one CTLA4 checkpoint inhibitor, useful in the immunotherapy of tumors and in the treatment of one or more HDAC6-mediated diseases.

Abstract: The present invention relates to novel selective oxadiazole-based inhibitors of histone deacetylase 6 (HDAC6) bearing a pentaheterocyclic scaffold and pharmaceutical compositions thereof.

Abstract: The present invention relates to novel benzohydroxamic compounds of formula (I) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

Abstract: The present invention relates to novel benzohydroxamic compounds of formula (1) and (II) and pharmaceutically acceptable salts, isomers and prodrugs thereof, exhibiting a high selective inhibitory activity against histone deacetylase 6 (HDAC6) enzyme.

Abstract: The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.

Abstract: The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.

Abstract: The present invention relates to new benzo-N-hydroxy amide compounds of formula (I) and pharmaceutically acceptable salts, isomers and prodrugs thereof, which show a significant inhibitory activity on the proliferation of tumor cells and specifically of cancer stem cells.

Abstract: The present invention provides for a library of vectors comprising human HC-CDR3 regions of varying length, wherein the diversity of said library is focused on the HC-CDR3 region only and diversity has been optimized such that redundancy is reduced for short HC-CDR3 loops and coverage of HC-CDR3 region variants for longer loop lengths has been increased. The library of the present invention is displayed on phage for selection against target antigens.

Abstract: The process according to the present invention allows expression and isolation of polypeptides with the proteolytic activity of HCV NS3 protease in a pure, catalytically active form, and in amounts that are sufficient for discovery of NS3 protease inhibitors and for determination of the three-dimensional structure of the NS3 protease. A further subject of the present invention is a procedure that defines the chemical and physical conditions necessary for completion of the proteolytic activity of the above polypeptides. The invention further comprises new compositions of matter (expression vectors) containing nucleotide sequences capable of expressing the above mentioned polypeptides in culture cells. Finally, new compounds of matter are defined, suitable to measure the above proteolytic activity, and useful to develop NS3 protease inhibitors and therefore therapeutic agents for use against HCV. The figure shows the kinetic parameters of HCV NS3 protease using the S3 depsipeptide substrate (SEQ ID NO:45).